Want to see TMO full AI Analyst Report?
Operating Income by Segment
Shows the profitability of different business segments, highlighting which areas are driving earnings and where there may be opportunities or challenges.Life Sciences Solutions and Laboratory Products are the primary drivers of Thermo Fisher’s margin recovery, showing multi-quarter improvement that underpins management’s raised guidance and EPS outlook, though LSS hasn’t fully returned to its pandemic-era highs. Analytical Instruments is the clear weakness—volatile and hit by academic/government softness, tariffs and FX headwinds—posing the main near‑term downside to consolidated operating income. Specialty Diagnostics is steadying but lags. The Clario acquisition and buybacks lift reported growth and EPS, but higher leverage and cyclical instrument demand raise execution risk.
Date | Life Sciences Solutions | Analytical Instruments | Speciality Diagnostics | Laboratory Products |
|---|---|---|---|---|
Jun 30, 2026 | $1.04B | $424.00M | $334.00M | $936.00M |
Mar 31, 2026 | $954.00M | $355.00M | $313.00M | $778.00M |
Dec 31, 2025 | $1.05B | $583.00M | $324.00M | $925.00M |
Sep 30, 2025 | $968.00M | $429.00M | $321.00M | $868.00M |
Jun 30, 2025 | $919.00M | $325.00M | $306.00M | $825.00M |
Mar 31, 2025 | $834.00M | $399.00M | $304.00M | $731.00M |
Dec 31, 2024 | $952.00M | $666.00M | $273.00M | $828.00M |
Sep 30, 2024 | $845.00M | $451.00M | $293.00M | $773.00M |
Jun 30, 2024 | $865.00M | $439.00M | $299.00M | $745.00M |
Mar 31, 2024 | $840.00M | $400.00M | $294.00M | $744.00M |